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Reward encompasses multiple psychological processes, including motivation to earn a 
reward and the hedonic enjoyment of a reward.  Animal and human research supports roles for 
the dopamine and mu-opioid systems in facilitating motivation and hedonics, respectively.  Loss 
of interest (apathy) and pleasure (anhedonia) are core symptoms of Major Depressive Disorder, 
and patients often present with impairments in one or both of these reward processes.  Patient 
studies suggest that the cortico-striatal network shows disordered responses to reward processing 
and particularly implicate altered dopamine and opioid function.  However, gaps in 
understanding remain: 1) individual differences in the relationship between reward response and 
neurotransmitter function in depression and 2) the value of reward response as a predictor of 
antidepressant treatment response are both important areas for investigation. 
            This dissertation takes a multimodal neuroimaging approach to investigate the molecular 
and clinical correlates of disordered reward processing in depression.  We utilized two 
modalities: 1) a well-validated reward paradigm during functional magnetic resonance imaging 
(fMRI) acquisition to measure neural response to anticipatory and hedonic reward in depressed 
patients and 2) positron emission tomography (PET) scans to measure dopamine and mu-opioid 
x 
 
receptor binding.  Participants subsequently completed a 10-week antidepressant treatment 
regimen. 
            We investigated the relationship between striatal fMRI responses to reward and DA 2/3 
and mu-opioid receptor binding. We replicated fundamental relationships previously established 
in the literature: we showed that striatal response to reward anticipation is associated with striatal 
dopamine release and D2/3 receptor availability, whereas striatal response to reward outcome is 
associated with mu-opioid receptor availability in the thalamus.  Furthermore, anterior cingulate 
response to reward anticipation mediates a previously-established relationship between nucleus 
accumbens mu-opioid function and antidepressant treatment response. 
            These results further elucidate the molecular correlates of reward anticipation and 
hedonics in major depression and establish the anterior cingulate as a mediator of the relationship 



















Reward processing and the underlying biology of its subcomponents 
 Reward is a fundamental modulator of behavior, acting through reinforcement.  While 
often described as though it were a unitary process, accumulating evidence suggests reward may 
be more aptly used as an umbrella term encompassing multiple psychological processes.  Two 
such processes are the desire to earn a reward and the pleasure of experiencing a reward, here 
referred to as motivation and hedonics respectively.  Notably, motivated and hedonic behavior 
can be seen across multiple modalities of reward, including primary rewards such as food 
(Barbano & Cador, 2005), as well as secondary rewards such as money (Knutson et al., 2000).  
The psychological processes of motivation and hedonics likely interact, but are experimentally 
dissociable and may become uncoupled in psychiatric illness.  Furthermore, each is associated 
with neurotransmitter systems and neural circuitry that, similar to the behavioral processes they 
underlie, are different but overlap neuroanatomically and interact physiologically.  Specifically, 
the dopaminergic system is believed to be critical in facilitating motivated response, and the µ-




Dopamine and motivation.  The neurotransmitter dopamine has been implicated in both reward 
behavior and voluntary movement, and acts in part by modulating the sensitivity of postsynaptic 
medium spiny neurons (MSNs) in the striatum (Figure 1.1) to other types of input such as 
glutamate. 
 Dopamine acts primarily on postsynaptic G-protein coupled dopamine receptors, which 
fall into two families: D1-like (D1 and D5 subtypes) and D2-like (D2-D4 subtypes), and the 
effect of dopamine binding depends on the receptor-type to which it binds.  Binding of dopamine 
to D1-like receptors creates “up-states”, that is, increased responsiveness of the MSN to 
sustained release of glutamate (Surmeier et al., 2007).  These receptors are stimulated by phasic 
firing, in which a rapid burst of action potentials leads to a rise in the release of dopamine at the 
target synapse (Grace & Bunney, 1984).  Conversely, binding of dopamine to D2-like receptors 
creates “down-states”, in which MSN responsiveness is reduced (Hernández-López et al., 2000).  
D2-like receptors are stimulated by tonic dopamine release, driven by the basal, steady-state 
firing of dopamine neurons. 
 The synthesis of dopamine begins with the conversion of tyrosine to L-3,4-
dihydroxyphenylalanine (L-dopa) by tyrosine hydroxylase.  L-dopa is subsequently converted to 
dopamine via decarboxylation, and is then stored in vesicles and released into the synapse in 
response to an action potential.  Dopamine undergoes rapid reuptake into the presynaptic 
terminal by the dopamine transporter (DAT), where it may be repackaged in vesicles for future 
release or degraded by monoamine oxidase (MAO) into homovanillic acid (HVA).  HVA can 
subsequently be measured in cerebrospinal fluid as an indirect measure of dopamine system 
function (Blennow et al., 1993). 
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Dopamine neurons in the ventral tegmental area (VTA) and substantia nigra pars 
compacta (SNpc) give rise to three major dopaminergic pathways (Figure 1.2; orange, yellow, 
and purple projections).  The mesolimbic pathway connects the VTA with the ventral striatum 
(including the nucleus accumbens; NAc) and amygdala, and is closely associated with 
motivational aspects of reward.  The nigrostriatal pathway connects the SNpc with dorsal 
striatum (caudate and putamen) and is mostly strongly associated with motor control.  The 
mesocortical pathway connects the VTA with cortical regions such as the dorsomedial prefrontal 
cortex, orbitofrontal cortex, and anterior cingulate cortex, and may play a role in aspects of 
executive function, such as attentional and inhibitory control. 
 Previous literature implicates the mesolimbic dopamine system in the desire for reward.  
Augmentation of DA transmission in rats via electrical stimulation (Berridge & Valenstein, 
1991), DAT knockdown (Peciña et al, 2003) and drug sensitization (Tindell et al, 2005; Wyvell 
& Berridge, 2000) induces increased feeding motivation, but with no increase in demonstrated 
hedonic enjoyment.  Likewise, disruption of DA transmission reduces motivation, while hedonic 
facial responses remain intact (Berridge & Robinson, 1998; Peciña et al, 1997) as does 
preference for sucrose solutions and highly palatable foods.  This link between motivation and 
dopamine has been demonstrated in humans as well, with DA levels correlating more highly 
with subjective levels of craving than pleasure (Leyton et al., 2002; Volkow et al., 2002).  DA 
antagonists do not reduce subjective ratings of pleasure for a drug but do diminish craving 
(Leyton, 2002).  Circuitry underlying motivation appears to comprise a larger cortico-striatal-
thalamic-cortical loop (Haber, 2011), working in parallel with anatomically similar loops 
underlying a variety of cognitive processes (Figure 1.3).  Special focus has been given to 
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mesolimbic pathway, although accumulating optogenetics evidence supports a role for the 
nigrostriatal pathway as well (Ilango et al., 2014; Rossi et al., 2013). 
 
Opioids and hedonics.  The endogenous opioid system is perhaps most well-known for its role in 
analgesia, but is further implicated in mood and hedonic reward. 
 Endogenous opioid ligands are classically known to bind to three G-protein coupled 
receptors: mu- (MOR), delta- (DOR), and kappa- (KOR) opioid receptors.  Unlike dopamine 
receptors, opioid receptors are expressed diffusely in the brain, and can be found throughout the 
cortex, limbic system and thalamus.  Animal models have suggested different roles for each 
receptor-type in mediating behavior, with MOR essential in the response to natural and drug 
rewards (Matthes et al., 1996; Papaleo et al., 2007), DOR in emotional regulation and drug-
reinforcement (Filliol et al., 2000; Roberts et al., 2000), and KOR activity eliciting aversive 
reactions, potentially maintaining hedonic homeostasis through the opposition of MOR effects 
(Spanagel et al., 1992).  Three major precursor proteins are cleaved to produce endongenous 
opioid ligands: proopiomelanocortin (POMC) into β-endorphins, proenkephalin (Penk) into 
enkephalins, and prodynorphin (Pdyn) into dynorphins.  Although the receptor binding profiles 
of endogenous opioid ligands are complex, generally MOR show high affinity for β-endorphins 
and enkephalins, DOR for enkephalins, and KOR for dynorphins. 
The µ-opioid system seems to play a critical role in the evaluation of the pleasant hedonic 
properties of a stimulus that make it desirable.  MOR are densely expressed in the nucleus 
accumbens, amygdala and medial thalamus.  In MOR knockout mice, the reinforcing properties 
of opiate (Contarino et al., 2002) and non-opiate (Berrendero et al., 2002; Ghozland et al., 2002; 
Roberts et al., 2000) drugs were abolished.  Human studies have similarly found that a MOR 
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antagonist decreased the perceived pleasantness of food, without changing the rated appetite 
(Yeomans & Gray, 1997).   
Relative to motivation, reward hedonics appear to be mediated by a more restricted 
limbic circuit.  Within striatal structures, such as the nucleus accumbens and ventral pallidum, 
are small hedonic “hotspots” (Peciña & Berridge, 2005; Smith & Berridge, 2005), containing a 
high density of opioid receptors.  Opioid stimulation of these regions elicits positive hedonic 
facial reactions to a sweet solution, and potently induces feeding.  These hedonic hotspots are 
found within structures also implicated in motivation, which illustrates an overlap in the circuitry 
underlying these different reward processes, and suggests the striatum as a potential site of 
interaction between them.   
 
Neuroimaging insight into the circuitry of reward processing.  The use of functional 
neuroimaging studies of reward in humans has largely replicated the general findings of the 
animal literature.  In the context of motivation, striatal BOLD responses to potential cocaine 
reward correlate positively with craving (Breiter et al., 1997).  The striatum also demonstrates 
increased response to conditioned cues predicting primary (O’Doherty et al., 2002) and 
secondary (Knutson et al., 2000) rewards.  Similarly, fMRI studies demonstrate significant 
response of the striatum to rewarding or positive outcomes, including for concrete outcomes such 
as money (Delgado et al., 2000) as well as more abstract hedonic rewards such as viewing an 
attractive face (Smith et al., 2010). 
While fMRI studies investigating reward processing have used a variety of paradigms, of 
particular interest is the Monetary Incentive Delay (MID) task (Knutson et al, 2000), which 
allows for investigation of the neural circuitries underlying motivation and hedonics within the 
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same task design.  In the task, participants have the opportunity to win and lose money based on 
their performance on a reaction-time challenge.  Responses to cues indicating potential gain 
serve as measures of reward anticipation and motivation, while responses to feedback indicating 
actual gain serve as measures of reward hedonics. 
 
Interim summary.  Reward processing is comprised of multiple subcomponents, including 
motivation and hedonics.  Motivation has been associated with the dopaminergic system, in 
particular the mesolimbic pathway connecting the VTA and ventral striatum.  Hedonic response 
has been associated with the endogenous opioid system, in particular mu-opioid receptors, and is 
believed to be facilitated by “hedonic hotspots”, areas of dense MOR expression including the 
ventral striatum.  Human neuroimaging experiments provide additional support for the striatum 
as a critical region for mediating both motivational and hedonic reward, with the Monetary 
Incentive Delay task serving as a well-validated paradigm for eliciting the neural circuitry 
underlying these processes. 
 Even as the field continues to develop its understanding of the psychological processes 
comprising reward, and the neurobiological systems that facilitate them, accumulating evidence 
implicates disruptions in reward processing in a variety of psychiatric conditions, including 
addiction, schizophrenia, and major depression.   
 
Major depression and disrupted reward processing 
 Major depression is a prevalent and debilitating illness, and represents a significant social 
and economic burden on society.  Characterized by depressed mood and a loss of pleasure, major 
depression affects an estimated 16.2% of adults in the United States at some point in their 
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lifetimes (Kessler et al., 2003).  The annual cost of MDD in the US is estimated at $83.1 billion, 
with nearly two thirds of this cost a result of functional disability (Greenberg et al., 1899).   
 With persistent depressed mood and loss of interest or pleasure as its core symptoms, 
major depression frequently includes other distressing symptoms such as fatigue, diminished 
ability to think or concentrate, and extreme alterations in sleep, appetite, or psychomotor 
behavior (American Psychiatric Association, 2013) (Figure 1.4).  Patients present with different 
constellations of these symptoms, resulting in a variety of clinical manifestations that all fall 
under the diagnosis of major depression.  For example, one patient may feel extreme sadness and 
worthlessness, frequently cry without understanding why, constantly fidget, overeat, and suffer 
from insomnia.  Another patient may feel bereft of emotion or pleasure, an inability to 
concentrate, fatigue, a lack of appetite and slowed movement.  While both symptoms profiles are 
undoubtedly burdensome on the affected individuals, they reflect different (and in some ways 
opposing) conditions that likely result from different etiologies.  This presents a challenge to the 
investigation of the biology of major depression, as samples are frequently heterogeneous and 
contain patients with different symptoms and etiologies, which may blur important individual 
differences driving their unique profiles.   
One way to address the challenge of heterogeneity in mental health research samples is 
reflected in the National Institute of Mental Health’s (NIMH) research domain criteria (RDoC) 
approach of examining functional domains that are disrupted in psychiatric illness, which may be 
more closely linked to alterations in underlying biology (i.e. abnormalities at the circuit, cellular, 
or molecular level) than the diagnoses themselves (Insel & Cuthbert, 2009).  With this in mind, it 
may be beneficial to focus on a disrupted functional process underlying a core symptom of the 
illness.   
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While much work has investigated the biology of disturbed emotion regulation in major 
depression (see Rive et al., 2013 for a review of the neuroimaging literature), the present work 
joins the body of literature investigating the biology of disrupted reward processing.  Individuals 
with MDD frequently present with reduced motivation (apathy) and pleasure (anhedonia).  In 
experiments with MDD patients, this disruption in motivation emerges behaviorally as reduced 
subjective positivity to anticipated rewards (McFarland & Klein, 2009) and reduced willingness 
to expend effort for rewards (Cléry-Melin et al., 2011; Treadway et al, 2009).  Converging lines 
of evidence support a role for dopaminergic dysfunction in the pathophysiology of depression, 
including reduced concentrations of the DA metabolite homovanillic acid (Lambert et al., 2000), 
and euphoric effects of DA receptor agonists (Tremblay et al, 2005) particularly in severely 
depressed patients (Tremblay et al, 2002).  The pro-depressive effect of catecholamine depletion 
in susceptible individuals (Hasler et al., 2009) further suggests a role of dopamine in mood 
dysregulation.  These data support the role of DA in motivation and a link between DA 
dysfunction and depression.   
 While experiments using self-report measures of pleasure generally fail to demonstrate 
impaired behavioral hedonic response in depression (Dichter et al., 2010), biological research 
does support a role for alterations of hedonic neural circuitry and the µ-opioid system in MDD 
pathology.  Evidence indicates that endogenous opioid system tone and activation is 
dysregulated in depression (Hsu et al., 2015; Kennedy, 2006), and opioid agonists elicit 
significant and rapid mood elevation in depressed patients (Ehrich et al., 2015).  Furthermore, in 
non-depressed participants, individual differences in µ-opioid function have been linked to 
affective responses (Liberzon et al., 2002; Zubieta et al, 2003).   
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 The human neuroimaging literature of reward processing in depression has produced 
heterogenous results, however a few consistent findings have emerged in meta-analyses.  First, 
striatal response to both reward anticipation and outcome is reduced in MDD patients relative to 
controls.  Second, medial prefrontal cortex (mPFC) and anterior cingulate cortex (ACC) response 
to reward anticipation is increased relative to controls (Zhang et al., 2015; Zhang et al., 2013) 
 
Interim summary.  The above literature identifies, in patients with major depression, alterations 
in behavior, neural circuitry, and neurotransmitter systems associated with different aspects of 
reward processing; most notably, reduced motivation, disrupted dopamine and opioid 
neurotransmission, and altered patterns of cortico-striatal response.  Substantial research has 
been performed to investigate the role of neurotransmitters in reward, the neural circuitry 
underlying different aspects of reward, and disruptions of these in MDD.  However, the 
relationships between motivation/DA and hedonics/µ-opioids are still not well-understood in 
depressed patients.  Given the above evidence that these reward processes and their associated 
neurotransmitter systems are disrupted in MDD, additional investigation is warranted into their 
respective contributions to the pathophysiology of depression (Figure 1.5).   
 
Molecular and clinical correlates of reward response 
 Previous research investigating the relationship between dopamine receptor activity and 
reward-related BOLD response supports the importance of cortico-striatal interactions in reward.  
In cocaine abusers, DA D2 receptor availability in the ventral striatum negatively correlates with 
mPFC BOLD response to reward outcome (Asensio et al., 2010).  Reward-elicited dopamine 
release in the ventral striatum is positively correlated with ventral striatal BOLD reward response 
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for both anticipation (Schott et al., 2008) and outcome (Weiland et al., 2016), and mPFC BOLD 
reward response to anticipation (Weiland et al., 2014). 
 Experiments investigating the link between BOLD reward response and clinical measures 
of disrupted reward behavior have thus far focused on schizophrenia, and demonstrate that 
ventral striatal response to reward anticipation correlates negatively with clinical measures of 
apathy (Kirschner et al., 2016; Simon et al., 2010) and anhedonia.  Interestingly, the negative 
relationship between reward response and anhedonia was not observed in patients with major 
depression (Arrondo et al., 2015).  
 
Interim summary.  The literature supports a link between ventral striatum dopamine function and 
reward responses in both the ventral striatum and mPFC, placing further emphasis on cortico-
striatal interactions in reward function.  In patients with schizophrenia, reduced ventral striatal 
response to reward is associated with greater apathy and anhedonia.  The nature of these 
relationships in individuals with depression remains unclear, although some evidence suggests 
the relationship may differ across diagnoses. 
 
Biomarkers for antidepressant treatment response 
The search for effective antidepressant treatment is challenging for many affected 
individuals. Following treatment with an initial SSRI antidepressant, an average of 4 weeks are 
needed to attain response and at least 6 weeks to attain remission, although remission can take 12 
weeks or longer, if achieved at all (Trivedi et al., 2006). Most patients fail to enter remission 
with the first antidepressant prescribed, and subsequently experience a period of serial trial-and-
error with different combinations of medications (Leuchter et al., 2009). It typically requires 1 
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year to identify a successful treatment (Keitner et al., 1992; Rush, 2007). Ineffective treatment 
carries a financial cost, in addition to side effects and the continued burden of the disease, 
making it difficult to maintain further compliance with treatment. Twenty-six percent of patients 
who fail to improve with the first treatment stop taking medication, frequently within the first 2 
weeks (Warden et al., 2007), and up to 42% of patients discontinue medication within the first 30 
days (Olfson et al., 2006). Given the rates of treatment failure, it is important to develop an 
understanding of which individuals are likely to respond to antidepressant treatment, and which 
are not.  
To address this issue, a growing body of research has focused on identifying predictors of 
antidepressant treatment response, primarily using neuroimaging techniques such as positron 
emission tomography (PET; Mayberg et al., 1997; Milak et al., 2009), electroencephalography 
(EEG; (Arns et al., 2015; Korb et al., 2009)), and functional magnetic resonance imaging (fMRI; 
Chen et al., 2007; Langenecker et al., 2007).  Some of these studies examined the brain at rest, 
and others while engaged in cognitive tasks such as face processing and response inhibition.  
And yet the function of reward circuitry, believed to be a component of the pathophysiology of 
major depression, remains understudied as a predictor of antidepressant treatment response 
(Phillips et al., 2015). 
 
Dopamine and µ-opioid systems in antidepressant treatment.  Given the robust evidence that 
dopamine and µ-opioid systems are disrupted in major depression, it is unsurprising that 
recovery from depression with treatment may affect these systems, and that modulation of these 
systems may impact depressive symptoms.  Studies investigating the impact of SSRI depressants 
on dopamine receptor binding have found mixed results: Montgomery et al. (2007) found 
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reduced DA D2/3 receptor availability in the dorsal striatum of patients with MDD taking SSRI 
antidepressants, compared to healthy controls.  Hirvonen et al. (2011) did not find a change in 
striatal DA D2/3 receptor availability following four months of SSRI treatment, but did note 
increased DA D2/3 receptor availability in the thalamus.  A meta-analysis of randomized, 
double-blind trials found norepinephrine/dopamine reuptake inhibitor buproprion to be equally 
effective as SSRIs (Thase et al., 2005), and it may be particularly effective in ameliorating 
anhedonia (Tomarken et al., 2004), which is frequently inadequately addressed by SSRIs.  
Similarly, recent trials of µ-opioid partial agonist buprenorphine have demonstrated reduced 
suicidal ideation in response to an ultra-low dose (Yovell et al., 2015), and reduction in 
depression scores in response to a low-dose in conjunction with a µ-opioid antagonist (Ehrich et 
al., 2015; Fava et al., 2016). 
 
Interim summary.  Difficulty in finding effective treatment, and the financial and emotional 
stress it engenders, represents an additional burden on patients with MDD.  A rapidly growing 
literature seeks to alleviate this burden by identifying pre-treatment predictors of treatment 
response.  While disrupted reward processing is a core symptom of major depression, and 
modulation of its associated neurotransmitter systems can elicit antidepressant effects, neural 




 Elucidating the underlying neurobiology of major depression, as well as the factors that 
influence response to available treatments, is critical to reducing the substantial personal and 
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societal burdens inflicted by the disease.  The current literature has established two key 
principles which motivate the present research.  First, anticipatory and hedonic reward behaviors 
are disrupted in depression, as are the neurotransmitter systems (DA/µ-opioid) and neural 
circuitry thought to underlie those behaviors.  Second, modulation of dopamine and µ-opioid 
systems can elicit antidepressant effects.  Pre-treatment measures of these systems, together with 
reward response, represent promising but understudied candidates for biomarkers of 
antidepressant treatment response.  Therefore, the present research seeks to clarify the 
relationship between disrupted neural reward response in depression and three measures with 
which it is putatively associated: dopamine/µ-opioid receptor activity, clinical scales of reward 
dysfunction, and antidepressant treatment response.  
 The experiments in the following chapters use two neuroimaging techniques: functional 
magnetic resonance imaging (fMRI) and positron emission tomography (PET), collected on the 
same sample of participants with major depression.  FMRI uses a magnetic field to measure 
changes in the concentration of oxygenated blood that occur in response to brain activity.  As 
previous literature has established impaired neural reward response in major depression, this 
technique provides us with a measure of the neural response to anticipatory and hedonic reward 
by having participants perform a Monetary Incentive Delay task during fMRI acquisition.  PET 
uses radiotracers to observe metabolic activity; more specifically, it can be used to investigate 
the availability of certain receptor types as well as the change in availability in response to a 
challenge.  A decrease in receptor availability for the radiotracer in response to a challenge 
would be interpreted as activation of the endogenous system; that is, increased release of the 
endogenous ligand.  Given the putative alterations in dopamine and µ-opioid systems in major 
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depression, this technique provides us with a measure of DA D2/3 and MOR availability, as well 
as dopamine and opioid peptide release in response to a challenge. 
 First, we investigate how anticipatory and hedonic reward response are associated with 
individual differences in DA D2/3 and MOR availability, as well as clinical measures of apathy 
and anhedonia, in patients with major depression.  This work builds on previous literature 
examining the relationship between dopamine neurotransmission and reward response, as well as 
previous work linking reward response and clinical scales of reward. 
 Second, we investigate how anticipatory and hedonic reward responses predict 
subsequent antidepressant treatment response, as well as how this relationship can be modelled 
in the context of dopamine and µ-opioid receptor binding.  This work adds to previous findings 
of neuroimaging predictors of treatment response in depression. 
Overall, the present research seeks to build on the field’s current knowledge of disrupted 
neural response to anticipatory and hedonic reward in major depression by exploring 
relationships with dopamine and µ-opioid receptor activity, clinical reward disruption, and 













Figure 1.1.  Dopaminergic neurotransmission at a striatal synapse.  Tyrosine is converted 
through a multistep process into dopamine.  Dopaminergic neurons projecting to the striatum 
synapse onto medium spiny neurons (MSNs) and may bind to a D1-like receptor (increasing 
MSN responsiveness to glutamate) or a D2-like receptor (decreasing MSN responsiveness to 
glutamate).  Dopamine in the synapse undergoes reuptake by a dopamine transporter and is 






Figure 1.2.  Major dopaminergic pathways.  The mesolimbic dopamine pathway (orange) is 
thought to play a critical role in reward processing.  The nigrostriatal pathway is involved in 
motor control, although accumulating evidence suggests it also has a role in reward.  Reprinted 













Figure 1.3.  Cortico-striatal-thalamic-cortical loops underlying motivation and other 








Figure 1.4.  DSM-V criteria for diagnosis of Major Depressive Disorder.  Anhedonia is one 







Figure 1.5.  RDoC approach to investigating disrupted reward in major depression.  The 
relationships between DA/reward anticipation and µ-opioid/reward outcome (red box) in patients 
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Anticipatory and Hedonic Reward Responses in Major Depression 





Individuals with Major Depressive Disorder (MDD) frequently present with a disruption 
in healthy reward processing.  Disrupted reward represents a core symptom of the illness, and 
has emerged in behavioral (Cléry-Melin et al., 2011; McFarland & Klein, 2009; Treadway et al., 
2009) and neuroimaging (Forbes et al., 2009; Pizzagalli et al., 2008; Smoski et al., 2009) studies 
of reward with depressed patients. Reward processing alterations in MDD encompass two major 
components: the desire to seek rewards (loss of interest) and the pleasure of experiencing 
rewards (loss of pleasure).  Each component is likely to be associated with distinct – and 
experimentally dissociable – neurotransmitter systems and neural circuitry.   However, the 
molecular substrates of these alterations are still not well understood.   
 
Motivation and dopamine.  Previous literature implicates the mesolimbic dopamine (DA) system 
in the desire for reward.  Augmentation and disruption of DA transmission in rodents (Berridge 
& Robinson, 1998; Berridge & Valenstein, 1991; Peciña et al., 1997; Peciña, et al., 2003; Tindell 
et al., 2005; Wyvell & Berridge, 2000) and humans (Leyton et al., 2002; Volkow et al., 2002) 
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reveals manipulation of motivation without affecting hedonic response.  The circuitry underlying 
motivation appears to comprise a larger cortico-striatal-thalamic-cortical network (Haber, 2011), 
and special focus has been given to mesolimbic pathway, connecting DA neurons in the ventral 
tegmental area (VTA) with the nucleus accumbens (NAc).   Converging lines of evidence 
support a role for DA dysfunction in the pathophysiology of depression, including altered striatal 
DA binding (Cannon et al, 2008), and reduced concentrations of a DA metabolite (Lambert et al, 
2000).  Furthermore, augmented (Tremblay et al, 2005) and disrupted (Hasler et al., 2009) DA 
neurotransmission in depressed individuals can exert anti- and pro-depressant effects, 
respectively. 
 
Hedonics and µ-opioids.  Studies investigating hedonics in both rodents and humans have 
implicated the µ-opioid system in the evaluation of the pleasant hedonic properties of a stimulus 
that make it desirable (Berrendero et al., 2002; Contarino et al., 2002; Ghozland et al., 2002; 
Roberts et al., 2000; Yeomans & Gray, 1997).  Relative to motivation, reward hedonics appear to 
be mediated by a more restricted limbic circuit: the NAc and ventral pallidum contain small 
hedonic “hotspots” (Peciña & Berridge, 2005; Smith & Berridge, 2005), which have a high 
density of opioid receptors.  Stimulation of the µ-opioid receptor in these regions elicits positive 
hedonic facial reactions to a sweet solution, and potently induces feeding.  In non-depressed 
participants, individual differences in µ-opioid function have been linked to affective responses 
(Liberzon et al., 2002; Zubieta et al, 2003). In depression, evidence indicates that endogenous 
opioid tone is dysregulated (Kennedy et al., 2006), and opioid modulation elicits significant and 
rapid mood elevation in depressed patients (Ehrich et al., 2015), although their usefulness in 




Clinical and molecular correlates of anticipatory and hedonic reward response.  Here, we 
investigate the molecular correlates of an extensively-used reward processing fMRI paradigm, 
the Monetary Incentive Delay (MID) task (Knutson et al, 2000) in twenty-nine patients with 
MDD.  We aimed to determine the relationship between fMRI responses during the anticipation 
of monetary gain, clinical measures of reward responsivity (self-reported measures of apathy and 
anhedonia), and in vivo correlates of opioid and DA receptor availability and release using 
Positron Emission Tomography (PET).  We hypothesized that (1) lower striatal fMRI responses 
to anticipation of monetary rewards would correlate with higher apathy scores, increased DA 
receptor binding, and reduced DA neurotransmission in the striatum.  We further hypothesized 
that (2) lower striatal fMRI responses to monetary rewards would correlate with higher 
anhedonia scores, increased µ-opioid receptor binding, and reduced opioid neurotransmission in 
the striatum.  
 
Methods 
Participants   
Written informed consent was obtained from all participants.  Procedures were approved 
by the University of Michigan Institutional Review Board for Human Subject Use and the 
Radioactive Drug Research Committee.   
Thirty-five right-handed medication-free participants were recruited via advertisement, 
and diagnosed with DSM-V Major Depressive Disorder (MDD; 23 females, age range 18 – 59 
years, mean ± SD: 32.09 ± 12.57) using the Mini International Neuropsychiatric Inventory 
(MINI) 6.0.  Inclusion criteria included diagnosis of MDD using the MINI and Hamilton Rating 
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Scale for Depression (HRSD; Hamilton, 1960) scores > 12.  At screening, participants completed 
the Apathy Evaluation Scale (AES; Marin, 1996) and Snaith-Hamilton Pleasure Scale (SHAPS; 
Snaith et al., 1995).  Exclusion criteria included suicidal ideation, comorbid medical, 
neurological or psychiatric conditions, pregnancy, and use of psychotropic agents.  
 
Study Design 
Full study design description has been previously described (Peciña et al, 2015). Briefly, 
patients were randomized to (1) 1-week "active" oral placebo treatment (2 pills per day), with 
expectations that it represented a fast-acting antidepressant agent, or (2) 1-week "inactive" oral 
placebo, with disclosure that it was an inactive control (Figure 2.1). After a 3-day washout period 
without pills, participants were crossed over into the group to which they were not previously 
assigned. After each placebo week, participants underwent a positron emission tomographic 
(PET) scanning session. As a challenge to induce endogenous opioid and DA system activation 
and determine acute placebo effects, the PET session following the 1-week active oral placebo 
included the administration of an IV active placebo. This consisted of 1mL of 0.9% isotonic 
saline-introduced IV every 4 minutes over 20 minutes, starting at minute 42 and lasting for 15 
seconds each time. Patients were made aware that the study drug was to be administered through 
a computer-generated human voice recording, followed by a second-by-second count of the 
infusion timing (15 seconds). No IV placebo followed the inactive placebo condition.  Following 
the 1-week inactive oral placebo, participants underwent a functional magnetic resonance 





Monetary Incentive Delay Task   
Participants performed a modified version of the MID task (Knutson et al., 2000) during 
fMRI acquisition, to measure changes in Blood-Oxygen-Level Dependent (BOLD) signal in 
response to reward anticipation and receipt.   Each participant completed three runs, of thirty 
trials each, in which subjects made a button-response to a simple visual target during a brief 
response window (Figure 2.2).   
At the beginning of each trial, participants saw a cue for 500ms, indicating the one of five 
trial conditions: potential large reward (+$5), potential small reward (+$0.20), potential large 
punishment (-$5), potential small punishment (-$0.20), or no money at risk (neutral).  Eighteen 
trials of each condition were presented in pseudo-randomized order.  An anticipation period of 
1500-5500ms followed the cue.  The target image then appeared briefly, cuing the participant to 
make a button response.  The participant won money or avoided losing money if the button was 
pressed within the response window (~250 ms).  The response window was dynamically varied 
over the course of the task, in response to participant reaction time.  Target presentation was 
followed by a variable delay (2-6 s) and then feedback regarding the outcome of the trial (2 s).  
An inter-trial interval of 2-6 s separated each trial. 
Participants’ responses to the MID task were recorded in E-Prime 2.0.  Behavioral 
responses were subsequently inspected to verify the correct response button was used.  Trials in 
which an incorrect response button was used were discarded from analysis.   
 
MRI acquisition and image processing 
MRI data were acquired on a Philips Ingenia 3.0-Tesla scanner (Philips Medical Systems; 
Best, Netherlands).  Two-hundred eleven whole-brain functional images were acquired in each 
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of three runs using a T2*-weighted echo-planar gradient-echo pulse sequence (39 slices acquired 
sequentially in axial orientation co-planar with AC-PC line, slice thickness = 3.5mm, slice gap = 
0mm, echo time = 28ms, repetition time = 2000ms, flip angle = 90°, acquisition matrix = 64mm 
x 64mm).  Stimuli were presented electronically with E-Prime 2.0 software (Psychology 
Software Tools, Pittsburgh, PA) using the ESys patient display monitor (Invivo, Orlando, FL). 
A high resolution structural image was obtained for anatomic normalization using a T1-
weighted, magnetization-prepared rapid gradient echo (MPRAGE) sequence (220 sagittal slices, 
slice thickness =1 mm, echo time = 4.6ms, repetition time = 9.8ms, flip angle=8°, acquisition 
matrix = 240mm x 240mm). 
Preprocessing was performed on the functional data using FSL (5.0.2.2, 
http://www.fmrib.ox.ac.uk) and SPM8 (r4667, Wellcome Department of Cognitive Neurology, 
University College London, UK; www.fil.ion.ucl.ac.uk). Volumes underwent slice-timing and 
motion correction.  Runs containing between-scan translation of more than 3.5mm were 
excluded, and participants with two or more excluded runs were excluded from group analysis.   
Data for six participants were rejected for excessive head motion during the fMRI scan.  
Functional scans were normalized to the MNI152 template, resampled to 2x2x2mm voxels, and 
underwent spatial smoothing using an isotropic Gaussian kernel of 8.0 mm full-width at half-
maximum.  Following all exclusions, fMRI data for twenty-nine participants were included in 
subsequent group analyses. 
For each participant, intrasubject effects were modeled in SPM8 using an event-related 
design including both anticipatory and outcome conditions.  For anticipatory conditions, the 
onsets of the cues for each of the five conditions were modeled as separate regressors.  For 
outcome conditions, onsets of the feedback period for each of the three potential outcomes 
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(successful monetary outcome, encompassing both monetary reward and avoidance of monetary 
punishment; unsuccessful monetary outcome, encompassing monetary punishment and failure to 
earn monetary reward; neutral outcome, where no money was at risk) were modeled as separate 
regressors.  In each model, six motion parameters were included as regressors of no interest.  A 
high pass filter (cutoff 128s) was applied, as well as AR(1) auto-regression correction.   
To investigate BOLD response to reward anticipation, a contrast was created for 
Anticipation of Monetary Gain > Neutral Anticipation (Anticipation of Monetary Gain collapsed 
across reward magnitude to encompass all trials in which participations could gain money).  
Anticipation of Monetary Loss > Neutral Anticipation showed similar results to the Monetary 
Gain contrast.  The Monetary Gain contrast was used in subsequent analyses to address our 
hypotheses regarding reward function in MDD. 
To investigate BOLD response to reward outcome, a contrast was created for Successful 
Monetary Outcome > Unsuccessful Monetary Outcome.  A contrast was also created for 
Unsuccessful Monetary Outcome > Successful Monetary Outcome, in which no significant 
results were observed.   
The number of observations of a given condition varied across the three runs.  To account 
for this, contrast weights were calculated to reflect inverse variance.  We determined the contrast 
weight for a given condition in a given run as the number of observations of the condition in that 
run, divided by the sum of the square roots of the number of observations of the condition in 
each run.  For example, the contrast weight for Condition A in run 1 is equal to the number of 
observations of Condition A in run 1 divided by the sum of the square roots of the number of 





PET acquisition and image processing 
Four 90-minute PET scans were acquired (HR_scanner; Siemens, Knoxville, Tennessee) 
in 3-dimensional mode (reconstructed full-width/half-maximum resolution, approximately 5.5 
mm in plane and 5.0 mm axially), with the septa retracted and scatter correction, as previously 
described (Peciña et al, 2015; Scott et al., 2007). Of the twenty-nine participants with quality 
fMRI data, all twenty-nine underwent PET scans for MOR; a subset of seventeen underwent 
scans for DA D2/3. 
Briefly, participants were positioned in the PET scanner gantry, and 2 intravenous 
(antecubital) lines were placed. A light forehead restraint was used to eliminate intrascan head 
movement. Radiotracer administrations were separated by at least 2 hours to allow for 
radiotracer decay.  Carbon 11 (11C)–labeled carfentanil was synthesized at high specific activity 
(>2000 Ci/mmol [the conversion factor for 1Ci is 3.7x1010 Bq]) by the reaction of [11C]methyl 
iodide and a normethyl precursor as previously described (Jewett, 2001). [11C]raclopride was 
synthesized at high specific activity (>2000 Ci/mmol) by the reaction of O-desmethyl raclopride 
with [11C]methyl triflate. Ten to 15 mCi was administered in each of the imaging procedures, 
with a mean (SD) mass of carfentanil injected of 0.028 (0.013) μg/kg per scan and of raclopride 
of 0.20 (0.15) μg/kg per scan. These levels ensured that the compounds were administered in 
tracer quantities, that is, subpharmacological doses occupying less than 1% of the available 
receptors. Fifty percent of the radiotracer doses were administered as an initial bolus and the 
remaining 50% by continuous infusion for the remainder of the study. This procedure 
compensates for the metabolism and distribution of the radiotracer, leading to constant plasma 
concentrations over time and more rapid equilibration between kinetic compartments. For each 
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scan, 21 sets of images (frames) were acquired over a 90-minute period with an increasing 
duration (four 30-second frames, three 1-minute frames, two 2.5-minute frames, eight 5-minute 
frames, and four 10-minute frames). Images were reconstructed using iterative algorithms (brain 
mode; Fourier rebinning algorithm with ordered-subsets expectation maximization, 4 iterations, 
and 16 subsets; no smoothing) into a 128x128-pixel matrix in a 28.8-cm-diameter field of view. 
Attenuation correction was performed through a 6-minute transmission scan (Ge68 source) 
obtained before the PET study and with iterative reconstruction of the blank/transmission data, 
followed by segmentation of the attenuation image. Small head motions during PET were 
corrected by an automated computer algorithm for each subject before analysis, and the images 
were co-registered with the same software. Time points were then decay corrected during 
reconstruction of the PET data. Image data were then transformed on a voxel-by-voxel basis into 
2 sets of parametric maps, a tracer transport measure (K1 ratio) and a receptor-related measure 
(distribution volume ratio [DVR] at equilibrium), using data from 5- to 40-minute post-tracer 
administration. To avoid the need for arterial blood sampling, these measures were calculated by 
means of a modified Logan graphical analysis (Logan et al., 1996) using the following reference 
regions: the occipital cortex (an area with low expression of μ-opioid receptors) for 
[11C]carfentanil scans and the cerebellum (an area with negligible DA D2/3 receptors) for 
[11C]raclopride scans. The slope of the Logan plot is equal to the receptor concentration divided 
by its affinity for the radiotracer (f2Bmax/Kd + 1 for this receptor site) and has been referred to as 
the DVR; f2Bmax/Kd (or DVR−1) is the “receptor related” measure (also termed BP) or receptor 
availability in vivo. Bmax is the receptor concentration and Kd, the receptor-ligand dissociation 
constant. The term f2 refers to the concentration of free radiotracer in the extracellular fluid and 
is considered to represent a constant and very small value. Reductions in the in vivo availability 
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of receptors, the BPND measure, after an acute challenge (i.e., placebo administration) are 
thought to reflect processes, such as competition between radiotracer and endogenous ligand, 
associated with neurotransmitter release (Narendran & Martinez, 2008). 
 
Clinical scales 
The AES-S is an 18-item self-report instrument measuring motivational impairment.  
Participants respond to statements regarding motivation on a four-point scale, indicating whether 
each statement is “not at all true”, “slightly true”, “somewhat true”, or “very true”.   Responses 
to each item are scored 4 to 1 respectively (with three items reverse-scored), such that total 
scores may range from 18 to 72, with higher scores indicating greater apathy (impairment in 
motivation). 
The SHAPS is a 14-item self-report instrument measuring hedonic experience.  
Participants respond to statements regarding experienced pleasure on a four-point scale, 
indicating whether they “strongly disagree”, “disagree”, “agree”, or “strongly agree” with each 
statement.  Responses of “strongly disagree” and “disagree” are scored 1, while responses of 
“agree” and “strongly agree” are scored 0, such that total scores may range from 0 to 14, with 
higher scores indicating greater anhedonia (impairment in hedonic function). 
 
Statistical analysis 
For overall flow of analyses in Chapter 2, see Figure 2.4.  At the second level, main 
effects of task were investigated using fMRI contrasts of interest (Anticipation of Monetary Gain 
> Neutral Anticipation; Successful Monetary Outcome > Unsuccessful Monetary Outcome).  We 
chose to look at Anticipation of Monetary Gain, rather than Monetary Loss, as our interest is in 
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anticipation of reward rather than avoidance of punishment.  That said, BOLD response to 
Anticipation of Gain and Loss did not significantly differ in main effect regions.  We similarly 
chose to investigate Successful Monetary Outcome > Unsuccessful Monetary Outcome to look at 
positive-valence specific response to reward hedonics.  Unsuccessful Monetary Outcome > 
Successful Monetary Outcome did not produce any significant results. 
The resulting voxelwise maps were thresholded at p < 0.001 uncorrected and with cluster 
extent threshold to correct for multiple comparisons at p < 0.05, based on Monte Carlo 
simulation using 3dClustSim (10000 iterations, NN1, 1-sided; version AFNI_16.2.01, 
precompiled binary linux_xorg7_64: July 8 2016; Cox, 1996).  For each contrast of interest 
(anticipation and outcome), a mask was generated comprised of significant Main Effect of Task 
clusters, restricted to the striatum using a mask of DA D2/3 binding (see Appendix 2.1). 
Functional MRI contrast values were extracted separately from each of these masks via 
the MarsBaR toolbox (Brett et al, 2002), and regressed against maps of DA D2/3 and µ-opioid 
receptor availability, and challenge-induced changes in receptor availability.  The resulting 
voxelwise maps were thresholded at p < 0.001 uncorrected.  Cluster extent threshold to correct 
for multiple comparisons at p < 0.05 was calculated using 3dClustSim as described above.  
Results were masked to the striatum using a mask of raclopride binding.  As a secondary 
analysis, correlations with maps of µ-opioid receptor availability were re-examined masked to 
regions of carfentanil binding. 
Additional statistical analyses were performed using the statistical software SPSS 22 
(IBM Corp, Armonk, NY).  Post-hoc, DA D2/3 and µ-opioid receptor availability values were 
extracted from significant clusters resulting from correlation analyses as binary cluster masks in 
MarsBaR.  These extracted values were correlated with fMRI contrast variables in SPSS. 
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Extracted fMRI contrast values for anticipation of monetary gain and successful monetary 
outcome were correlated with Apathy Evaluation Scale and Snaith-Hamilton Pleasure Scale 
scores.  For SPSS correlations, in cases where variables were non-normally distributed (as 
determined by Shapiro-Wilk test of normality in SPSS, p < 0.05), Spearman’s rank correlation 
coefficient (ρ) was tested.  For all others, Pearson’s correlation coefficient (r) was used. 
 
Results 
Clinical characteristics of sample 
Participants’ scores on the Apathy Evaluation Scale ranged from 25-66 (mean ± SD = 
46.00 ± 9.11).  Scores on the Snaith-Hamilton Pleasure Scale ranged from 0-12 (mean ± SD = 
5.42 ± 3.51). 
 
Behavioral results 
 Median reaction time of successful responses across all trial types was 217.7ms (± 56.0 
ms).  Mean accuracy across all trial types was 54.7% (± 7.8%).  For additional behavioral results, 




Relationship between striatal DA D2/3 and µ-opioid BPND and striatal anticipation of monetary 
gain during the MID 
We first examined the relationship between the anticipation of monetary gain in the 
striatum during the MID and binding measures of DA D2/3 (n = 17) and µ-opioid (n = 29) 
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receptors.  Averaged BOLD signal from striatal main effects of task during the anticipation of 
monetary gain was regressed against both DA D2/3 and µ-opioid binding maps.  
Increased striatal BOLD response during anticipation of monetary gain correlated 
positively with DA D2/3 receptor BPND in the bilateral putamen (Right putamen: 30, -10, 6; z = 
4.86, k = 136; left putamen: -26, -14, 6; z = 4.08, k = 49), and right caudate (16, 12, 16; z = 4.25, 
k = 138).  Increased striatal BOLD response during anticipation of monetary gain correlated 
negatively with DA D2/3 receptor BPND in the right globus pallidus (26, -6, -6; z = 3.97; k = 
115).  (Figure 2.5) 
No effects were observed between striatal BOLD response during the anticipation of 
monetary gain and striatal µ-opioid receptor binding potential for either positive or negative 
contrasts. 
 
Relationship between DA D2/3 and µ-opioid BPND and striatal processing of successful 
monetary outcomes during the MID 
 
We next examined the relationship between the processing of successful monetary 
outcomes during the MID and measures of DA D2/3 (n = 17) and µ-opioid (n = 29) receptor 
availability.  Averaged BOLD signal from a mask incorporating the main effects of task within 
the striatum during the processing of successful monetary outcomes (see Methods), was 
regressed against both DA D2/3 and µ-opioid binding maps.   
No significant correlations were observed between BOLD response in the striatum during 
successful monetary outcomes and striatal DA D2/3 receptor availability for either positive or 
negative contrasts. 
No significant correlations were observed between BOLD response in the striatum during 
successful monetary outcomes and striatal µ-opioid receptor availability for either positive or 
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negative contrasts.  Using a larger mask reflecting areas of µ-opioid receptor binding (see 
Appendix 2.3), increased BOLD response to successful monetary outcome correlated negatively 
with µ-opioid receptor availability in the bilateral medial thalamus (peak at 2, -12, 4; z = 3.36; k 
= 65) (Figure 2.6).   No significant correlations were observed for the opposite contrast. 
 
Relationship between challenge-induced changes in DA D2/3 and µ-opioid BPND and striatal 
anticipation of monetary gain during the MID 
 
We then examined the relationship between challenge-induced changes in DA D2/3 (n = 
17) and µ-opioid (n = 29) BPND and the processing of anticipatory response to monetary gain 
during the MID, using the same mask described above for the anticipation of monetary gain.   
Increased BOLD response to anticipation of monetary gain correlated negatively with challenge-
induced changes in DA D2/3 BPND in the bilateral putamen (Figure 2.7; left putamen: -26, -2, 0; 
z = 3.90; k = 50; right putamen: 26, 4, 2; z = 4.09; k = 35).  No significant correlations were 
observed for the opposite contrast. 
No significant correlations were observed between BOLD responses during anticipation 
of monetary gain and challenge-induced changes in µ-opioid BPND, for either positive or 
negative contrasts. 
 
Relationship between challenge-induced changes in DA D2/3 and µ-opioid BPND and striatal 
processing of successful monetary outcomes during the MID 
 
Finally, we examined the relationship between challenge-induced changes in DA D2/3 (n 
= 17) and µ-opioid (n = 29) BPND and the processing of successful monetary outcomes during 
the MID, using the mask described above for the processing of monetary outcomes. 
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No significant correlations were observed between BOLD responses during successful monetary 
outcome and challenge-induced changes in DA D2/3 BPND or µ-opioid BPND, for either positive 
or negative contrasts. 
 
Relationship between anticipation-associated DA D2/3 BPND and clinical reward scales 
Building on the above analyses, we investigated the relationship between anticipation-
associated striatal DA D2/3 BPND, and clinical measures of reward function: apathy, measured 
by the AES, and anhedonia measures by the SHAPS.  Increased DA D2/3 BPND in the putamen 
and caudate was associated with greater anhedonia scores (r = .584, p = 0.014), and was 
associated at a trend level with greater apathy scores (r = .448, p = 0.071).  No significant 
correlation was observed between DA D2/3 BPND in the globus pallidus and apathy or 
anhedonia. 
 
Relationship between outcome-associated MOR BPND and clinical reward scales 
We also investigated the relationship between outcome-associated thalamic MOR BPND, 
and clinical measures of reward function.  No significant correlation was observed between µ-
opioid BPND in the thalamus and apathy or anhedonia. 
 
(See Table 2.1 for summary of significant imaging results.) 
 
Discussion 
In the present study, we investigated the relationship between striatal response during 
anticipation and receipt of a reward, neurotransmitter binding and neurotransmission, and 
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clinical measures of disrupted reward in patients with Major Depression.  The above results 
demonstrate significant relationships between DA D2/3 receptor availability, fMRI BOLD 
responses to anticipation of monetary gain, and self-reported measures of apathy and anhedonia.  
Specifically, we observed a positive correlation between BOLD response to anticipation of 
monetary gain and DA D2/3 receptor availability in the dorsal striatum, such that lower BOLD 
response was associated with lower striatal DA D2/3 receptor availability.  Given previous 
findings of both striatal hypoactivation to reward anticipation (Zhang et al, 2013) and elevated 
striatal DA D2/3 receptor availability (Meyer et al., 2006) in MDD, the direction of this finding 
was unexpected.  That said, investigations into altered DA D2/3 receptor availability in 
depression have produced mixed results (Savitz & Drevets, 2013), potentially as a result of 
confounding factors such as smoking status and the presence of psychomotor retardation. 
We did not observe the hypothesized correlation between BOLD response to successful 
monetary outcome and µ-opioid receptor availability in the striatum.  However, we did observe a 
negative correlation between BOLD response to successful monetary outcome and µ-opioid 
receptor availability in the medial thalamus (a key region of reward circuitry which receives 
projections from the striatum; Haber & Calzavara, 2009) such that lower BOLD response was 
associated with greater thalamic µ-opioid receptor availability.  These findings suggest that 
individuals with lower opioid tone in the thalamus demonstrate reduced neural reward response.  
However, this result does not survive cluster-threshold correction for multiple comparisons, and 
is at increased risk of reflecting type I error.  An alternate analysis, performed by extracting 
BOLD signal from Main Effect of Task clusters across the whole brain (instead of restricting to 
the striatum), replicated the negative correlation between BOLD response to successful monetary 
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outcome and µ-opioid receptor availability in the medial thalamus, and did survive cluster-
threshold correction for multiple comparisons (data not shown). 
Additionally, we observed a positive correlation between anticipation-associated striatal 
DA D2/3 receptor availability and scores on clinical scales of disrupted reward, such that greater 
anhedonia and apathy were associated with greater DA D2/3 receptor availability in the caudate 
and putamen.  This finding is in line with our hypothesis, suggesting lower endogenous tone of 
DA in individuals with greater clinical reward disruption. 
We further observed a significant negative correlation between BOLD reward response 
and dopamine neurotransmission in the bilateral putamen.  Previous studies have demonstrated a 
positive correlation between NAc dopaminergic release and anticipatory reward activation 
(Schott et al., 2008; Urban et al., 2011; Weiland et al., 2014), as well as activation to reward 
outcome (Weiland et al, 2016).  One notable consideration that may account for why we observe 
a different effect in both location (putamen vs nucleus accumbens) and direction (negative 
correlation with reward response vs positive) compared to the cited work is that previous studies 
have induced dopamine release using a reward-challenge, which may induce different patterns or 
magnitude of release than the placebo-challenge in the present study.  
In addition to testing our hypothesized relationships, we also observed a significant 
negative correlation between striatal BOLD response to reward anticipation and striatal BOLD 
response to successful monetary outcome in patients with MDD.  This relationship was 
unexpected but does parallel some previous findings.  de Leeuw et al. (2015) found a negative 
correlation between reward anticipation and outcome response in the ventral striatum of 
unaffected siblings of patients with schizophrenia.  Other studies have published findings in 
which BOLD response to reward anticipation and reward outcome are significantly correlated 
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with a third variable in opposite directions, but did not directly correlate the two BOLD measures 
(Forbes et al., 2010; Furukawa et al., 2014).  At least one study has directly tested this 
relationship and found no significant effect (Hoogendam et al., 2013).  We likewise found no 
significant relationship between anticipation and outcome response in a separate sample of 
control subjects (n = 13, p > 0.9, data not shown).  The negative relationship in patients with 
MDD could reflect variation among participants in how much they transfer incentive salience 
from the reward outcome to the reward cue.  Participants who fail to transfer this incentive 
salience may demonstrate reduced response to the cue (i.e., anticipation) while still 
demonstrating a response to reward outcome.  Additional investigation into the relationship 
between striatal responses to reward anticipation and reward outcome are warranted, in both 
healthy control subjects and clinical samples. 
The above findings should be interpreted with the following consideration in mind: 
anticipation of reward in the MID coincides with motor preparation for a button response (as 
noted in Treadway & Zald, 2011), such that striatal BOLD response during this condition likely 
reflects both processes, and must be interpreted with caution.  The role of striatal dopamine in 
both processes further strains our ability to interpret the above relationship between BOLD 
response and DA D2/3 binding.   
These results should be replicated with the inclusion of a healthy control group, which 
would allow direct comparison of neurotransmitter binding/reward response relationships 
between depressed and control samples.  Such a comparison would help to clarify the context of 
the above results, and allow for stronger statements about the molecular basis of reward 
disruption in major depression.  Furthermore, investigating the relationship between neural 
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response to reward and neurotransmission elicited by a reward-challenge in individuals with 
MDD would help place this work in context of previous studies. 
In summary, our results suggest that neural response to reward and clinical measures of 
reward response in depressed individuals are modulated by DA D2/3 and µ-opioid receptor 





















Tables, Figures, and Legends 
 
 
Figure 2.1. Study design. Participants were randomized into a 1-week active or inactive oral 
placebo treatment.  Following a three-day washout period, participants crossed over into the 
other group.  Following each treatment period, participants underwent a PET scanning session.  
Following the active oral placebo treatment, participants received a placebo IV during the PET 
scan.  Following the inactive oral placebo treatment, participants additionally underwent an 






Figure 2.2. Monetary Incentive Delay task design.  The MID is a reaction-time task probing 
reward function.  Participants receive a cue indicating condition-type (potential win, potential 
loss, or null).  Following a fixation cross, a target appears.  The participant makes a button-press 
as quickly as possible in the response to the target, and subsequently receives feedback 




















Figure 2.3. PET measures of binding and release.  In both the inactive and active placebo 
conditions, and for both [11C]raclopride and [11C]carfentanil, participants underwent two periods 
of PET scanning.  During the 45 minute – 90 minute session in the active condition, investigators 
introduced a placebo-challenge, meant to elicit dopamine and endogenous opioid release.  
Measures of receptor availability, or radiotracer “binding”, were taken from the baseline 5 
minute – 40 minute scan from the inactive condition.  Measures of “release”, or the change in 
binding in response to a challenge, were calculated by subtracting the image of the 45 minute – 
90 minute scan during active condition (which included placebo IV) from the image of the 45 







Figure 2.4. Work flow of analyses for Chapter 2.  We collected striatal BOLD response to 
reward anticipation and hedonics, as well as dopamine and opioid binding and release.  Extracted 
striatal anticipation and hedonic signals from the fMRI analyses were used as covariates in a 
voxelwise regression with PET binding and release maps.  In significant clusters from those 
analyses, PET signal was extracted and correlated with clinical measures of reward disruption 







Figure 2.5. Correlation between anticipatory responses to monetary reward and D2/D3 
receptor availability.  a) BOLD response to anticipation of monetary gain was positively 
correlated with DA D2/3 receptor availability in bilateral putamen (Right putamen: 30, -10, 6; z 
= 4.86, k = 136; left putamen: -24, 0, 10; z = 4.08, k = 49), and right caudate (16, 12, 16; z = 
4.25, k = 138) (n = 17).  Map is cluster-wise FWE-corrected at cluster-defining threshold p < 
0.001. Color bar reflects T-values.  b) Graph of post-hoc correlation between BOLD response to 
anticipation of monetary gain and DA D2/3 receptor availability averaged across significant 
clusters (ρ = .355).  c) BOLD response to anticipation of monetary gain was negatively 
correlated with DA D2/3 receptor availability in right globus pallidus (26 -6 -6; z = 3.97; k = 
115).  Map is cluster-wise FWE-corrected at cluster-defining threshold p < 0.001.  Color bar 
reflects T-values.  d) Graph of post-hoc correlation between BOLD response to anticipation of 







Figure 2.6. Correlation between response to successful monetary outcome and µ-opioid 
receptor availability.  a) BOLD response to successful monetary outcome is negatively 
correlated with µ-opioid receptor availability in bilateral medial thalamus (Left thalamus: -8, -16, 
6; z = 4.37; right thalamus: 12 -26 4, z = 4.10; k = 588; n = 29).  Map is thresholded at p < 0.001 
uncorrected.  Color bar reflects T-values.  b) Graph of post-hoc correlation between BOLD 
response to successful monetary outcome and µ-opioid receptor availability in the bilateral 
















Figure 2.7. Correlation between anticipation of monetary gain and challenge-induced 
change in DA D2/3 receptor availability.  a) BOLD response to anticipation of monetary gain 
is negatively correlated with challenge-induced change in DA D2/3 receptor availability in 
bilateral putamen (Left putamen: -26, -2, 0; z = 3.90; k = 50; right putamen: 26, 4, 2, z = 4.09; k 
= 35; n = 17).  Map is cluster-wise FWE-corrected at cluster-defining threshold p < 0.001.  Color 
bar reflects T-values.  b) Graph of post-hoc correlation between BOLD response to successful 
monetary outcome and challenge-induced change in DA D2/3 receptor availability in the 

















 Regiona Hb MNIc Cluster sized  Ze ρf 
A. Anticipation of monetary gain  
DA D2/3 BPND: Positive correlation  
 Putamen R 30 -10 6 1088 4.86 .355 
  L -26 -14 6 1104 4.08  
 Caudate R 16 12 16 392 4.25  
  
DA D2/3 BPND: Negative correlation  
 Globus pallidus R 26 -6 -6 920 3.97 -.360 
  
DA D2/3 ΔBPND: Negative correlation  
 Putamen R 26 4 2 280 4.09 -.613 
  L -26 -2 0 400 3.90  
  
 Regiona Hb MNIc Cluster sized  Ze rg 
B. Successful monetary outcome  
MOR BPND: Negative correlation  
 Thalamus L 2 -12 4 520 3.36 -.447 
a Anatomical region subjectively labeled following consultation of AAL, ICBM, and TD 
atlases 
b H: hemisphere 
c Montreal Neurological Institute (MNI) coordinates of peak voxel (mm) 
d Cluster size in mm3; bolded values indicates cluster size surpasses threshold to survive 
multiple comparison correction 
e Two-sided voxel-level Z score at peak voxel 
f Post-hoc: Spearman’s rank correlation coefficient, using average signal across clusters 
g Post-hoc: Pearson correlation coefficient  
 
Table 2.1. Summary of BOLD contrast correlations with PET binding potential. A. BOLD 
response to anticipation of monetary gain was correlated with DA D2/3 binding potential and 
challenge-induced changes in DA D2/3 binding potential.  B. BOLD response to successful 
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Appendix 2.1.  Masks for Main Effect of Task.   
 
 
Appendix Figure 2.8.  Anticipation of Monetary Gain.  A mask was constructed from the 
significant striatal Main Effect of Task clusters for the Anticipation of Monetary Gain > Neutral 









Appendix Figure 2.9. Successful Monetary Outcome.  A mask was constructed from the 
significant striatal Main Effect of Task clusters for the Successsful Monetary Outcome > 
Unsuccessful Monetary Outcome contrast (cluster-wise FWE-corrected at cluster-defining 












Appendix 2.2.  Behavioral Task Data. 
 
Behavioral measure  All trials Gain trials Null trials Loss trials 
Reaction time (ms) 217.7 ± 56.0 214.9 ± 60.9 234.2 ± 46.2 217.7 ± 53.7 
Accuracy (% correct) 54.7 ± 7.8 56.7 ± 10.3 44.1% ± 18.4 58.0 ± 11.4 
 
Appendix Table 2.2.  Behavioral Data for Monetary Incentive Delay task.  Median reaction 
time for successful responses and accuracy were measured during the Monetary Incentive Delay 
task.  Results are presented as mean ± SD both collapsed across trial conditions (All trials), and 


























Appendix Figure 2.10.  Mask indicating regions of DA D2/3 binding.  A mask was constructed 
from group raclopride binding maps and encompasses the striatum.  This mask was used when 









Appendix Figure 2.11. Mask indicating regions of µ-opioid receptor binding.  A mask was 
constructed from group carfentanil binding maps and encompasses whole brain, with the 
exception of occipital lobe and ventricles.  While our hypotheses regarding µ-opioid receptor 
binding focused on the striatum, this mask was used in secondary analyses to investigate the 















Anterior Cingulate Response to Reward Anticipation Predicts 




Major depression is a prevalent and debilitating illness, and represents a significant social 
and economic burden on society.  Characterized by depressed mood and a loss of pleasure, major 
depression affects an estimated 16.2% of adults in the United States at some point in their 
lifetimes (Kessler et al., 2003).  The annual cost of MDD in the US is estimated at $83.1 billion, 
with nearly two thirds of this cost a result of functional disability (Greenberg et al., 2003).  Much 
of this cost can be attributed to the long period of time it takes patients to recover from the illness 
in addition to the limited response to available treatments (Leuchter et al., 2009). 
The search for an effective treatment is challenging for many affected individuals. It 
typically requires 1 year to identify a successful treatment (Keitner et al., 1992; Rush, 2007). 
Ineffective treatment carries a financial cost, in addition to side effects and the continued burden 
of the disease, making it difficult to maintain further compliance with treatment.  
To address this issue, a growing body of research has focused on identifying predictors of 
antidepressant treatment response, primarily using functional neuroimaging techniques (Mayberg 
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et al., 1997; Arns et al., 2015; Langenecker et al., 2007; Chen et al., 2007).  And yet the function 
of reward circuitry, believed to be a component of the pathophysiology of major depression, as a 
predictor of antidepressant treatment response remains understudied (Phillips et al., 2015). 
Previous studies of incentive processing in individuals with major depression have found 
dysregulation in the underlying circuitry (Knutson et al., 2008; Pizzagalli et al., 2009). 
Associated neurotransmitter systems may also be affected: dopamine plays a critical role in 
experiencing the rewarding effects of incentives, and is proposed to be involved in disturbed 
incentive response in major depression (Nestler & Carlezon, 2006). However, while the literature 
of neurochemical dysregulation in depression has focused primarily on dopamine and its fellow 
monoamine neurotransmitters serotonin and norepinephrine, the opioid system represents an 
underexplored avenue for understanding the etiology and treatment of major depression.  
Endogenous µ-opioid tone is dysregulated in major depression (Kennedy et al., 2006), and 
treatment with µ-opioid agonists has been associated with significant mood improvement (Karp 
et al., 2014). Of particular interest are findings associating antidepressant treatment response 
with a µ-opioid receptor variant (Garriock et al., 2010) and pre-treatment µ-opioid tone in the 
nucleus accumbens (Peciña et al., 2015). The role of dopamine and opioid function in both 
incentive processing and major depression suggest that a multimodal approach, capturing both 
the function of reward circuitry and its associated neurotransmission, is needed to most 
effectively characterize incentive processing as a predictor of antidepressant treatment response.  
To address this question, we measured BOLD response to two reward processes 
(incentive anticipation and successful monetary outcome), and dopamine and µ-opioid function 
via PET, prior to a ten-week antidepressant trial.  We hypothesized that one or both of the 
following relationships would emerge: 1) striatal response to reward anticipation would correlate 
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with subsequent antidepressant treatment response, as well as striatal DA D2/3 receptor 
availability, and 2) striatal response to successful reward outcome would correlate with 
subsequent antidepressant treatment response, as well as striatal µ-opioid receptor availability. 
 
Methods 
Participants   
Written informed consent was obtained from all participants.  Procedures were approved 
by the University of Michigan Institutional Review Board for Human Subject Use and the 
Radioactive Drug Research Committee.   
Thirty-five right-handed medication-free participants were recruited via advertisement, 
and diagnosed with DSM-V Major Depressive Disorder (MDD; 23 females, age range 18 – 59 
years, mean ± SD: 32.09 ± 12.57) using the Mini International Neuropsychiatric Inventory 
(MINI) 6.0.  Inclusion criteria included diagnosis of MDD using the MINI and Hamilton Rating 
Scale for Depression (HRSD; Hamilton, 1960) scores > 12. Exclusion criteria included suicidal 
ideation, comorbid medical, neurological or psychiatric conditions, pregnancy, or use of 
psychotropic agents.   
Sixteen right-handed healthy control (HC) participants with no history of psychiatric 
illness (8 females, age range 20 – 47 years, mean ± SD: 30.25 ± 8.11) were recruited 
concurrently as part of a separate study, and screened using the MINI.   
 
Study design 
All participants performed a Monetary Incentive Delay task while functional magnetic 
resonance imaging (fMRI) data was collected.  MDD participants also underwent a positron 
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emission tomographic (PET) scanning session.  Following PET and fMRI scans, MDD 
participants began a 10-week open-label trial with the selective serotonin reuptake inhibitor 
citalopram (20-40 mg daily).  Depressive symptoms were evaluated at weeks 0, 2, 4, 8 and 10 
using the Quick Inventory of Depressive Symptomatology (QIDS-SR16) self-report measure 
(Rush et al, 2003).  Twenty-two of the 35 MDD participants (62.9%) completed the 10-week 
trial, with partial follow-up data available for all 35 participants. 
 
Monetary Incentive Delay Task  
Participants performed a modified version of the MID task (Knutson et al., 2000) during 
fMRI acquisition, to measure changes in Blood-Oxygen-Level Dependent (BOLD) signal in 
response to reward anticipation and receipt.   Each participant completed three runs, of thirty 
trials each, in which subjects made a button-response to a simple visual target during a brief 
response window.   
At the beginning of each trial, participants saw a cue for 500ms, indicating the one of five 
trial conditions: potential large reward (+$5), potential small reward (+$0.20), potential large 
punishment (-$5), potential small punishment (-$0.20), or no money at risk (neutral).  Eighteen 
trials of each condition were presented in pseudo-randomized order.  An anticipation period of 
1500-5500ms followed the cue.  The target image then appeared briefly, cuing the participant to 
make a button response.  The participant won money or avoided losing money if the button was 
pressed within the response window (~250 ms).  The response window was dynamically varied 
over the course of the task, in response to participant reaction time.  Target presentation was 
followed by a variable delay (2-6 s) and then feedback regarding the outcome of the trial (2 s).  
An inter-trial interval of 2-6 s separated each trial. 
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Participants’ responses to the MID task were recorded in E-Prime 2.0.  Behavioral 
responses were subsequently inspected to verify the correct response button was used.  Trials in 
which an incorrect response button was used were discarded from analysis.   
 
MRI acquisition and image processing.  
MRI data were acquired on a Philips Ingenia 3.0-Tesla scanner (Philips Medical Systems; 
Best, Netherlands).  Two-hundred eleven whole-brain functional images were acquired in each 
of three runs using a T2*-weighted echo-planar gradient-echo pulse sequence (39 slices acquired 
sequentially in axial orientation co-planar with AC-PC line, slice thickness = 3.5mm, slice gap = 
0mm, echo time = 28ms, repetition time = 2000ms, flip angle = 90°, acquisition matrix = 64mm 
x 64mm).  Stimuli were presented electronically with E-Prime 2.0 software (Psychology 
Software Tools, Pittsburgh, PA) using the ESys patient display monitor (Invivo, Orlando, FL). 
A high resolution structural image was obtained for anatomic normalization using a T1-
weighted, magnetization-prepared rapid gradient echo (MPRAGE) sequence (220 sagittal slices, 
slice thickness =1 mm, echo time = 4.6ms, repetition time = 9.8ms, flip angle=8°, acquisition 
matrix = 240mm x 240mm). 
Preprocessing was performed on the functional data using FSL (5.0.2.2, 
http://www.fmrib.ox.ac.uk) and SPM8 (r4667, Wellcome Department of Cognitive Neurology, 
University College London, UK; www.fil.ion.ucl.ac.uk). Volumes underwent slice-timing and 
motion correction.  Runs containing between-scan translation of more than 3.5mm were 
excluded, and participants with two or more excluded runs were excluded from group analysis.   
Data for six MDD participants were rejected for excessive head motion during the fMRI scan.  
Functional scans were normalized to the MNI152 template, resampled to 2x2x2mm voxels, and 
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underwent spatial smoothing using an isotropic Gaussian kernel of 8.0 mm full-width at half-
maximum. 
For each participant, intrasubject effects were modeled in SPM8 using an event-related 
design including both anticipatory and outcome conditions.  For anticipatory conditions, the 
onsets of the cues for each of the five conditions were modeled as separate regressors.  For 
outcome conditions, onsets of the feedback period for each of the three potential outcomes 
(successful monetary outcome, encompassing both monetary reward and avoidance of monetary 
punishment; unsuccessful monetary outcome, encompassing monetary punishment and failure to 
earn monetary reward; neutral outcome, where no money was at risk) were modeled as separate 
regressors.  In each model, six motion parameters were included as regressors of no interest.  A 
high pass filter (cutoff 128s) was applied, as well as AR(1) auto-regression correction.   
To investigate BOLD response to incentive anticipation, a contrast was created for 
Incentive Anticipation > Neutral Anticipation (Anticipation of Incentive collapsed across reward 
magnitude and valance to encompass all trials in which participations could gain or lose money).  
Anticipation of Monetary Loss and Anticipation of Monetary Gain did not differ significantly in 
main effect of task regions. 
To investigate BOLD response to reward outcome, a contrast was created for Successful 
Monetary Outcome > Unsuccessful Monetary Outcome.  A contrast was also created for 
Unsuccessful Monetary Outcome > Successful Monetary Outcome, in which no significant 
results were observed.   
The number of observations of a given condition varied across the three runs.  To account 
for this, contrast weights were calculated to reflect inverse variance.  We determined the contrast 
weight for a given condition in a given run as the number of observations of the condition in that 
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run, divided by the sum of the square roots of the number of observations of the condition in 
each run.  For example, the contrast weight for Condition A in run 1 is equal to the number of 
observations of Condition A in run 1 divided by the sum of the square roots of the number of 
observations of Condition A in run 1, run 2, and run 3.  
 
PET acquisition and image processing. 
Within the MDD cohort, four 90-minute PET scans were acquired (HR_scanner; 
Siemens, Knoxville, Tennessee) in 3-dimensional mode (reconstructed full-width/half-maximum 
resolution, approximately 5.5 mm in plane and 5.0 mm axially), with the septa retracted and 
scatter correction, as previously described (Peciña et al, 2015; Scott et al., 2007). Of the twenty-
nine participants with quality fMRI data, all twenty-nine underwent PET scans for MOR; a 
subset of seventeen underwent scans for DA D2/3. 
Briefly, participants were positioned in the PET scanner gantry, and 2 intravenous 
(antecubital) lines were placed. A light forehead restraint was used to eliminate intrascan head 
movement. Radiotracer administrations were separated by at least 2 hours to allow for 
radiotracer decay.  Carbon 11 (11C)–labeled carfentanil was synthesized at high specific activity 
(>2000 Ci/mmol [the conversion factor for 1Ci is 3.7x1010 Bq]) by the reaction of [11C]methyl 
iodide and a normethyl precursor as previously described (Jewett, 2001). [11C]raclopride was 
synthesized at high specific activity (>2000 Ci/mmol) by the reaction of O-desmethyl raclopride 
with [11C]methyl triflate. Ten to 15 mCi was administered in each of the imaging procedures, 
with a mean (SD) mass of carfentanil injected of 0.028 (0.013) μg/kg per scan and of raclopride 
of 0.20 (0.15) μg/kg per scan. These levels ensured that the compounds were administered in 
tracer quantities, that is, subpharmacological doses occupying less than 1% of the available 
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receptors. Fifty percent of the radiotracer doses were administered as an initial bolus and the 
remaining 50% by continuous infusion for the remainder of the study. This procedure 
compensates for the metabolism and distribution of the radiotracer, leading to constant plasma 
concentrations over time and more rapid equilibration between kinetic compartments. For each 
scan, 21 sets of images (frames) were acquired over a 90-minute period with an increasing 
duration (four 30-second frames, three 1-minute frames, two 2.5-minute frames, eight 5-minute 
frames, and four 10-minute frames). Images were reconstructed using iterative algorithms (brain 
mode; Fourier rebinning algorithm with ordered-subsets expectation maximization, 4 iterations, 
and 16 subsets; no smoothing) into a 128x128-pixel matrix in a 28.8-cm-diameter field of view. 
Attenuation correction was performed through a 6-minute transmission scan (Ge68 source) 
obtained before the PET study and with iterative reconstruction of the blank/transmission data, 
followed by segmentation of the attenuation image. Small head motions during PET were 
corrected by an automated computer algorithm for each subject before analysis, and the images 
were coregistered with the same software. Time points were then decay corrected during 
reconstruction of the PET data. Image data were then transformed on a voxel-by-voxel basis into 
2 sets of parametric maps, a tracer transport measure (K1 ratio) and a receptor-related measure 
(distribution volume ratio [DVR] at equilibrium), using data from 5- to 40-minute posttracer 
administration. To avoid the need for arterial blood sampling, these measures were calculated by 
means of a modified Logan graphical analysis (Logan et al., 1996) using the following reference 
regions: the occipital cortex (an area devoid of μ-opioid receptors) for [11C]carfentanil scans and 
the cerebellum (an area with negligible DA D2/3 receptors) for [11C]raclopride scans. The slope 
of the Logan plot is equal to the receptor concentration divided by its affinity for the radiotracer 
(f2Bmax/Kd + 1 for this receptor site) and has been referred to as the DVR; f2Bmax/Kd (or DVR−1) 
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is the “receptor related” measure (also termed BP) or receptor availability in vivo. Bmax is the 
receptor concentration and Kd, the receptor-ligand dissociation constant. The term f2 refers to the 
concentration of free radiotracer in the extracellular fluid and is considered to represent a 
constant and very small value. Reductions in the in vivo availability of receptors, the BPND 
measure, after an acute challenge (i.e., placebo administration) are thought to reflect processes, 
such as competition between radiotracer and endogenous ligand, associated with 
neurotransmitter release (Narendran & Martinez, 2008). 
 
Statistical analysis 
For work flow of analyses, see Figure 3.1.   
At the second level, fMRI contrasts of interest (Incentive Anticipation > Neutral 
Anticipation; Successful Monetary Outcome > Unsuccessful Monetary Outcome) were regressed 
in separate analyses against reduction in depressive symptoms with antidepressant treatment 
(QIDS-SR16 Week 0 – Week 10).  The resulting voxelwise maps were thresholded at p < 0.001 
uncorrected.  The cluster-extent threshold to correct for multiple comparisons at p < 0.05 was 
calculated based on Monte Carlo simulation using 3dClustSim (10000 iterations, NN1, 1-sided; 
version AFNI_16.2.01, precompiled binary linux_xorg7_64: July 8 2016; Cox, 1996). 
BOLD signal from significant clusters was extracted via the MarsBaR toolbox (Brett et 
al, 2002), and regressed against maps of DA D2/3 and µ-opioid receptor availability.  The 
resulting voxelwise maps were thresholded at p < 0.001 uncorrected.  Again, the cluster-extent 
threshold to correct for multiple comparisons at p < 0.05 was calculated using 3dClustSim. 
Additional statistical analyses were performed using the statistical software SPSS 22 
(IBM Corp, Armonk, NY).  MDD were divided into high- (n=12) and low- (n=10) antidepressant 
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responder groups using a median split, based on participants’ change in QIDS-SR16 scores from 
week 0 to week 10 of the antidepressant clinical trial.  A one-way analysis of variance (ANOVA) 
was performed on the extracted response to incentive anticipation, between healthy controls, 
low-antidepressant responder MDD, and high-antidepressant responder MDD.  Mediation 
analysis was performed using a bootstrapping approach with 5000 bootstrap samples, as 




Healthy control and MDD participant samples did not significantly differ in age or gender.  
MDD participants reported significantly higher depressive symptoms at screening, as measured 
by the QIDS-16-SR, t(49) = 9.80, p < 0.001 . 
 
Behavioral results 
Healthy control and MDD participants did not significantly differ on accuracy or median 
reaction time for successful responses either overall, or specifically in gain trials, loss trials, and 
null trials (data not shown). 
 
Imaging results 
Relationship between incentive anticipation and successful monetary outcome during the MID 
and subsequent antidepressant treatment response  
We first examined the relationship between antidepressant treatment response and 
responses to incentive anticipation and successful monetary outcome during the MID.  Decreases 
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in depressive symptoms after ten weeks of antidepressant treatment, as measured by Quick 
Inventory of Depressive Symptomatology (QIDS-SR16) self-report measure (Rush et al, 2003) 
were regressed against anticipation and outcome contrast maps.  
Clinical improvement with treatment negatively correlated with BOLD response to 
anticipatory incentive processing in a mediofrontal cluster encompassing aspects of rostral 
anterior cingulate cortex (rACC), dorsal anterior cingulate cortex (dACC), and medial prefrontal 
cortex (mPFC) (-6, 50, 24, z = 4.22, k = 229; n = 22; Fig 3.2a), such that greater BOLD response 
predicted poorer treatment response (Fig 3.2b).  (NOTE: In the interest of brevity, for the 
remainder of this document the significant cluster reported in this paragraph is referred to as 
rACC).  No significant correlations were observed for the opposite contrast. 
Low antidepressant responders (n = 10) demonstrated significantly increased rACC 
BOLD response to incentive anticipation relative to high antidepressant responders (n = 12) and 
healthy controls (n = 13) (F = 11.8, p < 0.001; Fig 3.2c). 
No significant correlations were observed between BOLD response to successful 
monetary outcome and antidepressant treatment response, for either positive or negative 
contrasts. 
 
Relationship between DA D2/3 and µ-Opioid BPND and rACC response to incentive anticipation  
We then examined the relationship between DA D2/3 (n = 17) and µ-opioid (n = 29) 
BPND and rACC response to incentive anticipation during the MID.  Rostral ACC response to 
incentive anticipation correlated negatively with µ-opioid BPND in the nucleus accumbens (right 
NAc: 10, 4, -8, z = 4.09, k = 105; left NAc: -20, 4, -8, z = 3.82; k = 223; Fig 3.3a), such that 
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greater rACC BOLD response was associated with reduced µ-opioid receptor availability (Fig 
3.3b).  No significant correlations were observed for the opposite contrast. 
No significant correlations were observed between rACC response to incentive 
anticipation and DA D2/3 receptor availability, for either positive or negative contrasts. 
 
Mediation analysis 
Given that rACC response to incentive anticipation was significantly correlated with µ-
opioid binding potential in the nucleus accumbens, and each of those variables independently 
predicted treatment outcome, we next performed a mediation analysis.  Two models were 
examined: in the first, we tested if rACC response to incentive anticipation mediated the 
relationship between NAc mu-opioid binding potential and treatment outcome.  In the second, 
we tested if NAc mu-opioid binding potential mediated the relationship between rACC response 
to incentive anticipation and treatment outcome. 
 
Model 1: Mediation of rACC response to incentive anticipation on NAc MOR BPND 
prediction of antidepressant treatment outcome 
 We observed that rACC response to incentive anticipation is a significant mediator of 
NAc MOR BPND effects on antidepressant treatment outcome (Sobel test: Z = 2.16, p = 0.031).  
Controlling for mediation effect of the rACC response significantly reduced the association 
between NAc MOR BPND and treatment outcome (total effect c: b = 11.80, SE = 3.02, p = 0.009; 




Model 2: Mediation of NAc MOR BPND on rACC response to incentive anticipation 
prediction of antidepressant treatment outcome 
We observed that NAc MOR BPND is not a significant mediator of rACC response to 
incentive anticipation effects on antidepressant treatment outcome (Sobel test: Z = -1.39, p = 
0.164).  Controlling for mediation effect of the NAc MOR BPND did not significantly reduce the 
association between rACC response to incentive anticipation and treatment outcome (total effect 
c: b = -3.20, SE = 0.67, p = 0.001; direct effect c’: b = -2.30, SE = 0.87, p = .0164) (Figure 3.4b). 
 
For full SPSS output of mediation analysis for Model 1, see Appendix 3.1. 
 
Discussion 
In the present study, we examined the association between two aspects of reward 
processing – anticipation and outcome – and antidepressant treatment response, as well as the 
role of associated neurotransmitters.  We found that response to reward anticipation was 
negatively associated with subsequent antidepressant treatment response, such that greater 
response predicted reduced improvement.  We further found that rACC response to reward 
anticipation mediated a previously identified relationship between µ-opioid receptor availability 
in the nucleus accumbens and antidepressant treatment response (Peciña et al., 2015).  These 
findings hold important implications for understanding the neurobiological network underlying 
disrupted reward processing in Major Depression, and also for improving predictive models of 
individual treatment response. 
We observed a significant negative correlation between BOLD response to incentive 
anticipation in a mediofrontal region (including aspects of rACC, dACC, and mPFC) and 
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subsequent improvement with antidepressant treatment, which supports the hypothesis that 
individual differences in anticipatory reward response, but not reward outcome, predict treatment 
outcome.  This finding joins a significant body of literature implicating the ACC as a critical 
region in predicting antidepressant response (Arns et al., 2015; see Pizzagalli, 2011 for review).  
Interestingly, the literature is divided regarding the direction of the relationship.  While some 
studies find a positive relationship between ACC activity and treatment outcome, we join the 
body of literature demonstrating a negative relationship.  Possible explanations for this apparent 
discrepancy are highlighted by differences in methodology across studies.  First, many of the 
results demonstrating a positive relationship between ACC activity and treatment outcome were 
done using resting-state activity or metabolism instead of task-related response (Pizzagalli et al, 
2001; Mayberg et al, 1997).  Second, some previous studies have used treatments other than 
SSRI antidepressants, such as sleep deprivation or ketamine (Clark et al, 2006; Salvadore et al, 
2009), in which the mechanism of action and recovery is likely different.  There is clearly a 
variety of approaches used to investigate the relationship between ACC activity and treatment 
outcome in depression, and additional investigation is needed to better understand the impact of 
task, treatment-type, and neuroimaging technique.  That said, even as differences in methodology 
may impact the direction of the relationship, it is interesting that ACC function continues to be 
implicated in treatment response.  In investigating this relationship in the context of healthy 
controls, we observed that subsequent treatment low-responders demonstrated hyperactive rACC 
response to incentive anticipation compared to both controls and subsequent treatment high-
responders.   
We also observed that the treatment outcome-predictive BOLD response in the rACC 
was negatively correlated with µ-opioid (but not DA D2/3) receptor availability, specifically in 
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the nucleus accumbens.  This finding conflicts with our hypothesis that treatment outcome-
predictive BOLD response to reward anticipation would correlate with DA D2/3 binding.  The 
nucleus accumbens is rich in µ-opioid receptors, which are thought to be involved in hedonic 
reward processing rather than anticipatory reward processing (Peciña et al, 2006), although 
opioid receptor binding also modulates dopamine neurotransmission (Fields & Margolis, 2015).  
This provides a potential avenue for µ-opioid receptors to influence anticipatory reward 
processes via dopaminergic neurons in the striatum. 
We replicated a previously published positive correlation between µ-opioid receptor 
availability in the nucleus accumbens and subsequent improvement with treatment (Peciña et al., 
2015) using a subset of the published sample, i.e. participants who both completed the 10-week 
treatment trial and produced acceptable fMRI data.  This finding is in line with previous 
evidence suggesting a role for the endogenous opioid system in modulating treatment response 
(Kennedy et al, 2006), and the possibility of modulating opioid receptor activity to elicit 
recovery from depression (Ehrich et al., 2015). 
 Finally, we observed a mediation relationship in which rACC response to incentive 
anticipation mediates the relationship between µ-opioid receptor availability in the NAc and 
antidepressant treatment outcome.  Given that frontal-striatal loops are critical to motivated 
behavior and are thought to be affected in major depression, we speculate that these individual 
differences among participants in rACC response and MOR receptor availability may provide a 
glimpse of the neurobiology underlying capacity for recovery with antidepressants. 
However, a limitation of using a functional neuroimaging approach is that the observed 
relationships with treatment outcome are correlational.  While the present findings further 
characterize the relationship between reward response, antidepressant treatment outcome, and 
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neurotransmitter binding, additional research is needed to elucidate the mechanism (if such a 
mechanism exists) that links individual variation in anticipatory incentive response and NAc µ-
opioid receptor availability to treatment response.  
In this chapter, we have referred to the treatment-predictive reward cluster as rostral 
anterior cingulate cortex, although it crosses neuroanatomical borders into other regions such as 
dACC and mPFC.   While highly interconnected, these regions also have their own specific 
patterns of connectivity, and this approach is not meant to suggest these regions are homogenous.  
However, the approach does (albeit unintentionally) reflect a source of imprecision in the field, 
which is naming conventions for anatomical locations.  In reviewing the literature, the label of 
rostral anterior cingulate is used to refer to locations from subgenual cingulate all the way up to 
dorsal ACC and medial PFC.  This imprecision groups together findings from neuroanatomically 
distinct regions and may blur, rather than sharpen, what we might learn from those results. 
 In summary, we find that rostral anterior cingulate response to incentive anticipation 
predicts subsequent antidepressant treatment outcome, and mediates the relationship between µ-
opioid receptor availability in the nucleus accumbens and treatment outcome.  These results, 
taken in the context of established reward circuitry, suggest a potential cingulo-striatal 
dysfunction in a subset of patients with Major Depression which diminishes recovery with 
antidepressant medication.  Further investigation into the nature of this mechanism is needed to 






Tables, Figures and Legends 
 Healthy (n=16) Depressed (n=35) p-value 
Age in years (mean ± SD) 30.25 (± 8.11) 32.09 (± 12.57) p = .538 1 
Sex (male/female) 8/8 12/23 p = .286 2 
QIDS at screening (mean ± SD) 2.93 (± 2.40) 15.72 (± 4.59) p < 0.0011 
1 independent-sample t-test, 2-sided 
2 Pearson Chi-square, 2-sided 
 
Table 3.1.  Characteristics of healthy and depressed participants.  Healthy controls and MDD 
participants did not significantly differ in age or sex.  MDD participants had more severe 











Figure 3.1.  Work flow of analyses for Chapter 3.  (A) Treatment response was used as a 
covariate in a voxelwise regression against fMRI contrast maps of reward anticipation and 
reward outcome.  Signal was extracted from significant clusters and used as a covariate in a 
voxelwise regression against mu-opioid and dopamine binding maps. (B) We identified two 





             
Figure 3.2.  Correlation between incentive anticipation BOLD response and improvement 
with antidepressant treatment.  (a) Baseline BOLD response to incentive anticipation in the 
rostral anterior cingulate cortex (rACC) is negatively correlated with improvement in depressive 
symptoms with antidepressant treatment, as measured by the change in QIDS-SR16 from week 0 
to week 10 of treatment.  Map is thresholded at p < 0.001 uncorrected.  Color bar reflects T-
values.  (b) r = -.735  (c) Low antidepressant responders show a significantly hyperactive rACC 
response to incentive anticipation relative to healthy controls and high-antidepressant responders 






         
Figure 3.3. Correlation between µ-opioid binding and rostral ACC BOLD response to 
incentive anticipation.  (a) Baseline µ-opioid binding in the nucleus accumbens (NAc) is 
negatively correlated with rACC BOLD response to incentive anticipation.  Map is thresholded 









Figure 3.4.  Mediation analyses. a) Model 1 tests whether rostral anterior cingulate cortex 
(rACC) BOLD response to incentive anticipation (mediator) mediates the relationship between 
µ-opioid binding potential in the nucleus accumbens (NAc) (predictor) and antidepressant 
treatment response (outcome).  Path b denotes the relationship between rACC BOLD response to 
incentive anticipation and antidepressant treatment response, while controlling for the effect of 
µ-opioid binding in the NAc.  Direct effect c’ denotes the relationship between µ-opioid binding 
in the NAc and antidepressant treatment response, while controlling for the mediation effect.     
b) Model 2 tests whether µ-opioid binding potential in the NAc (mediator) mediates the 
relationship between rACC BOLD response to incentive anticipation (predictor) and 
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Appendix 3.1: SPSS output of mediation analysis for Model 1 (rACC mediator) 
 
Run MATRIX procedure: 
 
************* PROCESS Procedure for SPSS Release 2.16.1 ****************** 
 
          Written by Andrew F. Hayes, Ph.D.       www.afhayes.com 
    Documentation available in Hayes (2013). www.guilford.com/p/hayes3 
 
************************************************************************** 
Model = 4 
    Y = improve 
    X = NAC 
    M = rACC 
 
Sample size 






          R       R-sq        MSE          F        df1        df2          p 
      .6723      .4520      .6399    16.4978     1.0000    20.0000      .0006 
 
Model 
              coeff         se          t          p       LLCI       ULCI 
constant     8.0253     1.9946     4.0236      .0007     3.8645    12.1861 






          R       R-sq        MSE          F        df1        df2          p 
      .7646      .5846     9.7832    13.3709     2.0000    19.0000      .0002 
 
Model 
              coeff         se          t          p       LLCI       ULCI 
constant   -11.6077    10.4907    -1.1065      .2823   -33.5664    10.3511 
rACC        -2.3022      .8743    -2.6331      .0164    -4.1322     -.4721 
NAC          5.4607     3.5824     1.5243      .1439    -2.0377    12.9592 
 




          R       R-sq        MSE          F        df1        df2          p 
      .6581      .4331    12.6855    15.2766     1.0000    20.0000      .0009 
 
Model 
              coeff         se          t          p       LLCI       ULCI 
constant   -30.0831     8.8806    -3.3875      .0029   -48.6089   -11.5574 
NAC         11.8026     3.0197     3.9085      .0009     5.5032    18.1019 
 




Total effect of X on Y 
     Effect         SE          t          p       LLCI       ULCI 
    11.8026     3.0197     3.9085      .0009     5.5032    18.1019 
 
Direct effect of X on Y 
     Effect         SE          t          p       LLCI       ULCI 
     5.4607     3.5824     1.5243      .1439    -2.0377    12.9592 
 
Indirect effect of X on Y 
         Effect    Boot SE   BootLLCI   BootULCI 
rACC     6.3419     3.1363     1.2510    13.5193 
 
Partially standardized indirect effect of X on Y 
         Effect    Boot SE   BootLLCI   BootULCI 
rACC     1.3738      .6177      .2468     2.6518 
 
Completely standardized indirect effect of X on Y 
         Effect    Boot SE   BootLLCI   BootULCI 
rACC      .3536      .1545      .0885      .6984 
 
Ratio of indirect to total effect of X on Y 
         Effect    Boot SE   BootLLCI   BootULCI 
rACC      .5373      .3197      .0839     1.3108 
 
Ratio of indirect to direct effect of X on Y 
         Effect    Boot SE   BootLLCI   BootULCI 
rACC     1.1614   159.4378    -3.3576    46.9584 
 
R-squared mediation effect size (R-sq_med) 
         Effect    Boot SE   BootLLCI   BootULCI 
rACC      .3823      .1309      .1316      .6275 
 
Normal theory tests for indirect effect 
     Effect         se          Z          p 
     6.3419     2.9309     2.1638      .0305 
 
******************** ANALYSIS NOTES AND WARNINGS ************************* 
 
Number of bootstrap samples for bias corrected bootstrap confidence 
intervals: 
     5000 
 
Level of confidence for all confidence intervals in output: 
    95.00 
 
NOTE: Some cases were deleted due to missing data.  The number of such cases 
was: 
  38 
 
NOTE: Kappa-squared is disabled from output as of version 2.16. 
 
------ END MATRIX ----- 
 
















Summary of Results 
 In Chapter 2, we demonstrate three key relationships.  First, striatal response to reward 
anticipation is associated with striatal dopamine release and D2/3 receptor availability.  Second, 
reduced striatal response to reward outcome is associated with increased thalamic mu-opioid 
receptor availability.  Third, greater anticipation response-associated DA D2/3 receptor 
availability in the striatum is associated with increased scores of anhedonia and apathy.  These 
findings reinforce evidence from animal literature linking dopamine function with reward 
motivation and mu-opioid function with reward hedonics.  The medial thalamus has not been a 
major focus of investigations into disrupted reward function in depression, but as a part of the 
cortico-striato-thalamo-cortical reward loop and a site with dense expression of mu-opioid 
receptors, the relationship with striatal response to reward outcome merits further investigation. 
 In Chapter 3, we demonstrate that rostral anterior cingulate (rACC) response to reward 
anticipation predicts antidepressant treatment response, and furthermore mediates the 
relationship between NAc mu-opioid receptor availability and antidepressant treatment response.  
Previous research had identified NAc mu-opioid receptor availability (Peciña et al., 2015) and 
rACC activity as predictors of antidepressant treatment response (see Pizzagalli, 2011 for 
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review).  For the first time, however, the current findings provide evidence which joins those two 
predictors in a single model, and further emphasize the role of cortico-striatal interactions in 
major depression.  
 
Common Discussion 
Dopamine/opioid interaction.  In the present work, we used measures of dopamine and mu-
opioid receptor availability to separately examine relationships with anticipatory and hedonic 
reward response.  However, these systems interact in the ventral tegmental area and striatum, 
adding an additional layer of complexity onto interpretations of the above results.  Opioid 
binding regulates the mesolimbic and mesocortical dopamine pathways by disinhibition.  More 
specifically, endorphins and enkephalins bind to mu-opioid receptors on GABAergic 
interneurons in the VTA which tonically inhibit the VTA dopaminergic neurons.  Activating the 
MOR inhibits GABA release, stopping the tonic inhibition of the dopaminergic neurons and 
facilitating dopamine release in their limbic and cortical projections.  So while motivation may 
be generally associated with dopamine receptor binding and hedonics with MOR binding, 
interactions between the two systems suggest a more nuanced relationship guiding 
neurotransmitter modulation of reward response.  Similarly, dopamine and mu-opioid receptor 
binding are part of a larger reward network involving many neurotransmitters such as GABA, 
glutamate, and serotonin which may modulate, or be modulated by, dopamine and opioid 
activity. 
 
Multiple reward processes.  We have framed the observed reward processing in the context of 
reward anticipation (or motivation) and outcome (hedonics).  However, reward processing 
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encompasses many more psychological processes, some of which may also influence response in 
our task.  Our ability to identify the neural underpinnings of a psychological process can only be 
as good as our isolation of that process.  Here, it is difficult to parse out response to anticipation 
of reward (i.e. looking forward to something) and motivation (i.e. drive to earn something).  
These processes are often tightly interconnected, and may be further influenced by other reward 
processing like reinforcement and reward learning.  In progressing toward a fuller understanding 
of the biology of reward processing, progress will also need to be made in clarifying and 
delineating the many psychological processes that comprise reward response. 
 
Interpreting BOLD and PET signal.  In discussing measures of binding potential and BOLD 
response, we must be cognizant how these measures are derived.  Binding potential is the ratio 
between receptor density (Bmax) and the radioligand equilibrium dissociation constant (KD).  
Therefore, individual differences in binding potential between participants could reflect 
differences in the number of receptors, binding affinity (the inverse of KD) or the endogenous 
tone of the ligand.  So while binding potential provides a measure of available receptors across 
subjects, the specific neurobiological mechanism facilitating individual differences is not 
demonstrated.  BOLD signal reflects changes in the concentration of deoxyhemoglobin, which 
changes as a result of increased cerebral blood flow to a given location in the brain in response to 
neural activity.  Increases in BOLD response are therefore often interpreted as a proxy for 
increased neural firing, but may most closely reflect the summation of postsynaptic potentials 
(Logothetis et al., 2001).  While postsynaptic activity and action potentials may be highly 
correlated in many cases, changes in regional cerebral blood flow can occur independently of 
neural firing.  As the field’s understanding of the neurobiological basis of PET and BOLD 
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signals continue to develop, our ability to confidently interpret these signals and the individual 
differences they reflect will improve. 
 
Skilled vs unskilled reward.  In our implementation of the Monetary Incentive Delay task, we use 
a null condition as the baseline for our contrast, in which the subject is neither rewarded nor 
punished regardless of performance.  This is compared to a condition in which potential reward 
is dependent on subject performance, which we believe allows us to capture a measure of 
motivated or anticipatory response.  However, what if reward outcome was determined not by 
performance, but by luck?  How would anticipation and hedonic response change if rewards 
were meted out for reasons beyond the participant’s control, and how would that affect 
relationships with dopamine and mu-opioid receptor activity?  This question of skilled compared 
to unskilled anticipation is particularly interesting in the context of major depression, as it deals 
with the concept of locus of control.  One might hypothesize that healthy controls would show a 
greater difference in response to skilled versus unskilled anticipation, compared to MDD patients 
who may believe that receiving the reward is outside of their control in both conditions and 
therefore have demonstrate similar neural response in each.   
 
Limitations 
While the current findings identify relationships between PET binding and BOLD reward 
response in patients with major depression, it is difficult to say how these relationships reflect 
disordered reward processing.  Having a sample of healthy control subjects with both PET and 
fMRI scans to directly compare would allow a cleaner interpretation of whether the relationships 
observed in MDD are aberrant.   
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We experienced large signal dropout in the OFC and vmPFC of our fMRI data.  This 
dropout is an unfortunately persistent characteristic of data acquired with the echo planar 
imaging (EPI) pulse sequence, as our data was.  Given the putative role of these regions in 
reward processing, and particularly in hedonic reward, the relationships tested here must be 
considered incomplete. 
The correlative nature of these neuroimaging techniques provide description of 
associations between neural reward response and associated receptor function, but prevent us 
from drawing conclusions about causation and mechanisms.  Any such conclusions drawn from 
this data would be speculative.   
 
Future Directions 
Molecular and clinical correlates of reward network connectivity.  While we have used BOLD 
response from individual regions as covariates in the present analyses, we know that cognitive 
processes are not facilitated by individual brain regions in isolation.  Instead, networks of brain 
circuitry interact to give rise to behaviors like reward processing.  Investigations into disrupted 
reward processing in major depression have identified aberrant cortico-striatal functional 
connectivity (Admon et al., 2015).  Given that the interactions of the reward network are a level 
of complexity beyond what is examined here, a logical next step would be to investigate how 
individual differences in the functional connectivity of reward circuitry are related to 
neurotransmission, apathy and anhedonia, and treatment response. 
 
Moderators of differential treatment response.  The present work identifies rACC response to 
reward anticipation as a predictor of SSRI treatment response.   Future work may benefit from 
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attempting to identify modulators of differential treatment diagnosis (Phillips et al., 2015); that 
is, rather than isolating a biomarker which predicts response to a single treatment, attempt to find 
biomarkers that facilitate more effective recovery from depressive symptoms in one treatment 
compared to another, such as antidepressant medication vs psychotherapy, or SSRIs vs dopamine 
and norepinephrine reuptake inhibitors. 
 
Common or differential reward disruptions across disorders.  One of the benefits of the RDoC 
approach is the opportunity to investigate impairments of functional domains across diagnoses.  
Disordered reward function is a particularly good process for transdiagnostic investigation, and it 
seems to be a critical facet of many psychiatric conditions (Baskin-Sommers & Foti, 2015; 
Hägele et al., 2014), such as substance abuse and the negative symptoms of schizophrenia.  
Investigating reward across these diagnoses would help identify commonalities and differences 
in reward dysfunction, and provide a clearer, more complete picture of how motivation and 
hedonics can be disrupted. 
 
Inflammation and disrupted reward in MDD.  Many MDD patients have increased peripheral 
levels of inflammatory cytokines, indicating increased inflammation.  Recent research has begun 
to investigate the relationship between inflammation and reward circuitry in depression, and has 
found that increased levels of inflammatory biomarkers were associated with decreased 
corticostriatal functional connectivity during resting-state fMRI (Felger et al., 2015).  With this 
link established, a next step would be to test the relationship between inflammatory biomarkers 







 Major depression is a significant burden on affected individuals and on society as a 
whole.  There remains much that we do not yet understand about the complex biology underlying 
this heterogeneous disorder, leaving the field ill-equipped to improve on current treatments 
which prove inadequate for many patients.  Elucidating the disruptions which drive impairments 
in functional domains across psychiatric illnesses (such as impaired reward processing in 
depression, schizophrenia, addiction, etc), rather than looking for a single etiology that covers all 
patients within a diagnosis, represents a promising path to cope with heterogeneity in mental 
health research.  Identifying effective predictors of treatment response will help reduce the 
burden associated with failed treatment and bring about more timely recovery.  This work 
reinforces links between reward process and neurotransmitter function previously supported by 
the animal literature, and identifies a mediation effect integrating two previously identified 
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